Key result
This review outlines the current status of antiviral therapy for influenza, noting the availability of two effective drug classes and the need for further development against pandemic threats.
This review summarizes the current status and future targets for antiviral therapy against influenza, emphasizing the need for effective treatments against pandemic strains.
Answers are grounded in this paper and cite their sources.
Two antiviral classes are available for influenza; leaves open urgent development of agents against pandemic strains.
Influenza viruses are a leading cause of morbidity and mortality worldwide despite the availability of an effective vaccine. The emergence of highly pathogenic avian influenza viruses in southeast Asia, which can infect and kill humans and for which there is no vaccine, has heightened the need to establish a supply of effective antivirals. Two effective classes of anti-influenza drugs are currently available, and many attractive targets exist for further development. This review presents the current status of antiviral therapy of, and highlights the challenges presented by, the threat of pandemic influenza.
No takes yet. Share an insight, caveat, or question.
Jonathan A. McCullers (2005) conducted a review in Influenza. Antiviral therapy was evaluated. This review outlines the current status of antiviral therapy for influenza, noting the availability of two effective drug classes and the need for further development against pandemic threats.
Synapse has enriched 10 related papers. Consider them for comparative context: